Asclepius MedTech

What Asclepius MedTech does

Asclepius MedTech Limited is a Leeds-based, privately-held medical technology company developing SurgFit™, a remote patient assessment system for pre- and post-operative surgical care. The platform combines a Class IIa CE-marked biosensor patch worn on the chest (capturing vital signs, activity, posture, and temperature over a multi-day window), a patient-facing mobile application for clinically validated health questionnaires, and a clinical dashboard that aggregates continuous wearable data with clinician-entered observations. AI-driven predictive algorithms compute a 'fitness for surgery index' intended to support surgical timing, pathway planning, and discharge decisions by clinical teams.

The company targets NHS hospital trusts and surgical teams as its primary customers, positioning SurgFit as a tool to address the UK surgical backlog (cited at 7.4 million people on NHS treatment waiting lists) and reduce the £13.7 billion annual cost of post-operative complications and readmissions. The product has been validated through a 200-patient observational clinical study completed in 2024, co-designed with patient and public involvement (PPIE) via the Leeds NIHR Surgical Technologies MedTech Co-operative.

The commercial model is a B2B subscription/licensing approach selling quote-based to NHS and hospital procurement, with phased market entry planned for the UK in 2026, the EU in 2027, and Canada and the USA in 2028. Funding to date consists of non-dilutive grants from NIHR and a £100,000 Mayor of West Yorkshire Big Ideas Challenge award, plus investment from NLC European HealthTech Venture Builder. The company is pre-revenue, with 1–10 employees and a leadership team that pairs commercial medtech experience (CEO Michael Morgan-Curran, CTO Ramm Mylvaganam) with clinical and NHS market access advisors.

Name

Asclepius MedTech

Legal name

Asclepius MedTech Limited

Website

https://asclepius-medtech.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

Asclepius MedTech is a Leeds-based pre-revenue medtech company developing SurgFit™, a Class IIa biosensor-based remote patient monitoring platform with AI predictive algorithms for pre- and post-operative surgical assessment, targeting NHS hospitals ahead of a planned UK 2026 launch.

Ownership category

akta.pro rank

Product category

Remote Patient Monitoring

NAICS

Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Surgical, Perioperative & ERAS Pathway Tools (HLACAGAJ)

akta.pro secondary industries

Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI), Vital Signs Monitoring (Multi-parameter, Spot-Check & Continuous) (HLAHACAA)

Keywords

• Remote patient monitoring
• Preoperative surgical assessment
• Wearable biosensor devices
• Clinical decision support
• Physiological monitoring platform

Headquarters

HQ city

England

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. SurgFit™ Platform Licensing/Subscription: B2B revenue model selling to NHS hospitals and healthcare providers. Platform provides remote monitoring services enabling hospitals to transform pre-operative assessment and move services into communities.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Asclepius MedTech offers Surgfit™, a remote patient assessment system for pre-operative surgical assessment. A Class IIa regulated biosensor patch is worn on the chest for 7 days to record physiological data (vital signs, activity, posture, temperature), combined with app-based health questionnaires, and transmitted in real time to a clinical dashboard. AI predictive algorithms process the longitudinal multimodal dataset to calculate a fitness-for-surgery index for hospital surgical teams.

Product overview

Asclepius MedTech Limited offers the Asclepius Platform, a remote continuous physiological monitoring system for pre- and post-operative surgical assessment. The platform's flagship product is Surgfit™, which consists of a CE-marked Class IIa wearable biosensor patch worn on the chest, the Asclepius App for patient data collection and health questionnaires, and a clinical dashboard for hospital pre-operative teams to view real-time patient data. The platform integrates wearable sensor data with AI-powered predictive analytics to calculate patient fitness for surgery, enabling clinicians to make more informed decisions about surgical timing, pathway planning, and discharge.

Differentiator

Problem solved

Functional benefit

Brands

• Surgfit: Remote patient assessment system for pre- and post-operative surgical care using a Class IIa regulated biosensor patch worn on the chest to record physiological data about patient's fitness, combined with health questionnaire data transmitted in real-time and visualised on hospital pre-operative team's clinical dashboard.

Products and services

• Surgfit™ Remote Patient Assessment System The first remote patient assessment system for pre-operative surgical assessment. Combines a Class IIa regulated chest-worn biosensor patch recording continuous physiological data, a patient-facing app for health questionnaires, and a clinical dashboard with AI predictive algorithms to produce a fitness-for-surgery index for hospital pre-operative teams. Sold to NHS hospital trusts and surgical teams.

Quantifiable outcome

• 25% reduction in NHS readmissions, saving £300M per year
• +3 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Partnerships

Five partnerships are on record, tiered core and minor.

• NIHR (National Institute of Health and Care Research)coreStrategic or Co-development PartnerSignificant funding from NIHR for proof-of-concept and quantitative studies. Collaborated with NIHR Surgical Technologies MedTech Co-operative for PPIE and clinical expert focus groups. Additional product development funding. Supported large 200-patient observational clinical study in 2024.
• Yorkshire & Humber AHSNcoreStrategic or Co-development PartnerDr. Neville Young serves as Director of Enterprise and Innovation at Yorkshire & Humber AHSN and provides market access advisory. AHSN supports health innovation adoption across the region.
• Leeds NIHR Surgical Technologies MedTech Co-operativecoreStrategic or Co-development PartnerClinical collaboration for deep understanding of barriers to implementation and scalability, patient acceptability requirements, and co-design of clinical studies.
• University of Leeds / Bowel Cancer UK & RCS(Engl) Professor of SurgeryminorStrategic or Co-development PartnerProfessor David Jayne holds Bowel Cancer UK & RCS(Engl) Professor of Surgery role at University of Leeds. Provides clinical expertise and academic network access.
• NHScoreStrategic or Co-development PartnerNHS is both a partner and customer. Product aligns with NHS 10-Year Plan and supports NHS elective care recovery plan. Professor David Jayne is Honorary Consultant Surgeon at NHSLTHT.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Vivify Health (Optum): Remote patient monitoring platform used by health systems to manage patients pre- and post-procedure, including surgical pathways; competes for the same hospital RPM procurement slots.
• Biofourmis: AI-driven remote patient monitoring and predictive analytics platform that pairs continuous wearable biosensor data with clinical algorithms for hospital-at-home and post-discharge monitoring; directly comparable technology and commercial model.
• Current Health (acquired by Best Buy Health): Provides a continuous remote monitoring platform with a wearable biosensor and clinical dashboard for hospital and post-acute care, including surgical recovery use cases — a close functional analogue to SurgFit™.
• Huma (formerly Medopad): Digital health platform offering remote patient monitoring with regulated Class IIa software-as-a-medical-device capabilities across multiple therapeutic areas, including pre- and post-operative pathways; competes directly for hospital RPM budgets in the UK NHS and EU.

Emerging players

• AliveCor: Maker of regulated, consumer/clinical-grade wearable cardiac biosensors with AI interpretation; shares the wearable + AI + clinical dashboard paradigm even though its core indication is arrhythmia detection.
• iRhythm Technologies: Wearable, regulated biosensor-based cardiac monitoring company whose technology and regulatory pathway (Class II medical device with continuous ambulatory monitoring) is technologically analogous to Asclepius's biosensor patch.
• Caresyntax: Digital surgery platform that uses data and analytics to improve surgical outcomes and perioperative workflows; addresses the same surgical pathway problem with a different (OR-focussed) data capture approach.

Broad incumbents

• GE Healthcare: Major medtech incumbent offering patient monitoring solutions and perioperative care tools to hospitals; not focused exclusively on remote pre-op assessment but addresses overlapping clinical and budget priorities.
• Philips Remote Patient Monitoring: Large incumbent with broad RPM, wearable biosensor and clinical dashboard capabilities sold to hospitals globally; competes for the same NHS and EU procurement budgets as a wider portfolio player.

Others

• Hippocratic AI: AI-driven clinical workflow company whose predictive AI for healthcare is adjacent to Asclepius's fitness-for-surgery index; not a direct RPM competitor but a possible ecosystem partner or downstream competitor in clinical decision support.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/asclepius-medtech-limited

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Asclepius MedTech